QuidelOrtho Reports Q3 2026 Revenue Decline Amid China Pricing Pressures and Lower Respiratory Demand
QuidelOrtho (QDEL) reported third-quarter 2026 results characterized by a 12% decline in total revenue to $618.9 million, driven primarily by significant headwinds in the Chinese market and reduced demand for respiratory testing products. The company's China revenue plummeted 45% year-over-year due to distributor destocking and new nationwide pricing guidelines for In Vitro Diagnostics. To combat these pressures, management is implementing a cost transformation program projected to yield $80 million in annual savings by 2027, which includes enterprise restructuring. While the company reported a GAAP net loss of $53.8 million, it showed improvement in operating cash flow and free cash flow compared to the previous year through tighter working capital management.
Tickers: $QDEL
Topics: China market headwinds Cost transformation Respiratory testing demand Restructuring Revenue decline